These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 39012590)
1. Fine-Tuning the Epigenetic Landscape: Chemical Modulation of Epigenome Editors. Noviello G; Gjaltema RAF Methods Mol Biol; 2024; 2842():57-77. PubMed ID: 39012590 [TBL] [Abstract][Full Text] [Related]
2. Reader-Effectors as Actuators of Epigenome Editing. Kim SH; Haynes KA Methods Mol Biol; 2024; 2842():103-127. PubMed ID: 39012592 [TBL] [Abstract][Full Text] [Related]
3. In vivo epigenome editing and transcriptional modulation using CRISPR technology. Lau CH; Suh Y Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145 [TBL] [Abstract][Full Text] [Related]
4. Protocol for Allele-Specific Epigenome Editing Using CRISPR/dCas9. Rajaram N; Bashtrykov P; Jeltsch A Methods Mol Biol; 2024; 2842():179-192. PubMed ID: 39012596 [TBL] [Abstract][Full Text] [Related]
5. A modular dCas9-based recruitment platform for combinatorial epigenome editing. Swain T; Pflueger C; Freytag S; Poppe D; Pflueger J; Nguyen TV; Li JK; Lister R Nucleic Acids Res; 2024 Jan; 52(1):474-491. PubMed ID: 38000387 [TBL] [Abstract][Full Text] [Related]
6. Designing Epigenome Editors: Considerations of Biochemical and Locus Specificities. Yagci ZB; Kelkar GR; Johnson TJ; Sen D; Keung AJ Methods Mol Biol; 2024; 2842():23-55. PubMed ID: 39012589 [TBL] [Abstract][Full Text] [Related]
7. Chromatin Manipulation and Editing: Challenges, New Technologies and Their Use in Plants. Fal K; Tomkova D; Vachon G; Chabouté ME; Berr A; Carles CC Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419220 [TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity. Tadić V; Josipović G; Zoldoš V; Vojta A Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448 [TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas mediated epigenome editing for cancer therapy. Ansari I; Chaturvedi A; Chitkara D; Singh S Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620 [TBL] [Abstract][Full Text] [Related]
10. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing. Goubert D; Koncz M; Kiss A; Rots MG Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148 [TBL] [Abstract][Full Text] [Related]
11. Editing the Epigenome to Tackle Brain Disorders. Liu XS; Jaenisch R Trends Neurosci; 2019 Dec; 42(12):861-870. PubMed ID: 31706628 [TBL] [Abstract][Full Text] [Related]
14. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells. Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic editing: Dissecting chromatin function in context. Policarpi C; Dabin J; Hackett JA Bioessays; 2021 May; 43(5):e2000316. PubMed ID: 33724509 [TBL] [Abstract][Full Text] [Related]
16. Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing. O'Geen H; Tomkova M; Combs JA; Tilley EK; Segal DJ Nucleic Acids Res; 2022 Apr; 50(6):3239-3253. PubMed ID: 35234927 [TBL] [Abstract][Full Text] [Related]
18. Development of Locus-Directed Editing of the Epigenome from Basic Mechanistic Engineering to First Clinical Applications. Rots MG; Jeltsch A Methods Mol Biol; 2024; 2842():3-20. PubMed ID: 39012588 [TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 in epigenetics studies of health and disease. Sar P; Dalai S Prog Mol Biol Transl Sci; 2021; 181():309-343. PubMed ID: 34127198 [TBL] [Abstract][Full Text] [Related]